Kiniksa Pharmaceuticals International, plc

Listed Company

KNSACIK 0001730430NasdaqLarge AcceleratedPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

$677.56M

Net Income

$59.01M

Total Assets

$763.63M

Equity

$567.61M

Shares Out

—

Op. Cash Flow

$137.99M

KNSA$63.94+121.63% · past yearDBEQ Basic

Daily closing prices

Business

Kinikska Pharmaceuticals International, plc is a biopharmaceutical company developing and commercializing novel therapies for cardiovascular and inflammatory diseases with unmet medical need. The company markets ARCALYST, an IL-1α and IL-1β cytokine trap approved for recurrent pericarditis and other inflammatory conditions, and is advancing clinical-stage candidates KPL-387 and KPL-1161 targeting IL-1 signaling, as well as abiprubart targeting CD40-CD154 interaction. The company operates in the United States and internationally through direct commercialization and partnerships including licensing arrangements with Regeneron for ARCALYST and with Huadong for Asia-Pacific distribution rights.

Summary from 10-K filed 2026-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	678	423	270	220	39
Cost of goods sold	78	61	33	23	9
Collaboration expenses	230	128	57	24	—
Research and development	97	112	76	65	99
Selling, general and administrative	196	168	129	98	86
Total operating expenses	600	469	295	210	195
Income (loss) from operations	77	−46	−25	10	−157
Other income, net	12	9	9	1	97,000
Income (loss) before income taxes	89	−36	−17	11	−157
Benefit (provision) for income taxes	−30	−7	31	172	−1
Net income (loss)	59	−43	14	183	−158
Net income (loss) per share attributable to ordinary shareholders, basic	0.8	−0.6	0.2	2.64	−2.3
Net income (loss) per share attributable to ordinary shareholders, diluted	0.75	−0.6	0.2	2.6	−2.3
Weighted average ordinary shares outstanding, basic	74	71	70	69	69
Weighted average ordinary shares outstanding, diluted	79	71	72	70	69
Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax	138,000	−169,000	−38,000	110,000	−32,000
Total other comprehensive income (loss)	138,000	−169,000	−38,000	110,000	−32,000
Total comprehensive income (loss)	59	−43	14	183	−158

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	166	184	108	123	122
Short-term investments	248	60	98	68	60
Accounts receivable, net	16	42	21	13	4
Inventory	55	26	31	22	4
Prepaid expenses and other current assets	43	20	18	11	7
Total current assets	527	332	276	243	196
Property and equipment, net	2	662,000	734,000	2	3
Operating lease right-of-use assets	10	10	12	5	6
Other long-term assets	11	10	827,000	6	9
Intangible asset, net	15	16	17	18	19
Deferred tax assets	198	211	219	185	—
Total assets	764	581	526	460	233
Accounts payable	2	2	8	8	2
Accrued collaboration expenses	70	48	17	—	—
Accrued expenses	42	32	28	30	38
Operating lease liabilities	3	2	2	3	3
Other current liabilities	22	16	8	6	2
Total current liabilities	139	101	64	47	45
Non-current deferred revenue	32	32	12	12	—
Non-current operating lease liabilities	7	8	10	3	3
Other long-term liabilities	19	2	2	2	270,000
Total liabilities	196	142	87	64	48
Commitments and contingencies (Note 16)	—	—	—	—	—
Additional paid-in capital	1,030	960	917	888	860
Accumulated other comprehensive loss	−25,000	−163,000	6,000	44,000	−66,000
Accumulated deficit	−462	−521	−478	−492	−675
Total shareholders' equity	568	438	439	396	185
Total liabilities and shareholders' equity	764	581	526	460	233

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income (loss)	59	−43	14	183	−158
Depreciation and amortization expense	2	2	2	2	2
Share-based compensation expense	37	31	27	25	25
Non-cash lease expense	4	3	3	3	3
Net amortization (accretion) of discounts on short-term investments	−916,000	441,000	−1	−82,000	664,000
Net (gain) loss on disposal of property and equipment	−120,000	−24,000	179,000	33,000	103,000
Deferred income taxes	13	8	−34	−185	11,000
Prepaid expenses and other current assets	−22	−3	−7	−4	3
Accounts receivable, net	26	−20	−9	−9	−4
Inventory	−29	5	−10	−18	−4
Contract asset	—	—	8	−8	—
Other long-term assets	−1	−10	5	3	−3
Accounts payable	142,000	−6	347,000	6	1
Accrued expenses, accrued collaboration expenses and other current liabilities	37	44	17	−4	10
Operating lease liabilities	−3	−4	−3	−3	−3
Deferred revenue	—	20	261,000	12	—
Other long-term liabilities	17	−35,000	19,000	2	−535,000
Net cash provided by operating activities	138	26	13	6	−126
Proceeds from sale of property and equipment	—	25,000	—	91,000	—
Purchases of property and equipment	−2	−277,000	−130,000	−105,000	−415,000
Purchases of short-term investments	−387	−202	−205	−136	−157
Proceeds from the maturities of short-term investments	199	240	176	128	306
Net cash provided by (used in) investing activities	−189	38	−30	−8	129
Proceeds from issuance of Class A ordinary shares under incentive award plans and employee share purchase plan	41	17	4	3	6
Payments in connection with ordinary stock tendered for employee tax obligations	−8	−5	−2	−901,000	—
Net cash provided by financing activities	33	12	1	3	6
Net increase (decrease) in cash and cash equivalents	−18	76	−15	245,000	8
Cash paid for income taxes, net	3	2	6	11	1
Change in right-of-use asset as a result of new, modified, and terminated leases	3	2	10	3	2
Additions to property and equipment included in accrued expenses and other liabilities	83,000	153,000	54,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Kiniksa Pharmaceuticals International, plc's CIK number?

Kiniksa Pharmaceuticals International, plc's SEC CIK number is 0001730430 (1730430). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Kiniksa Pharmaceuticals International, plc's SEC filings?

All of Kiniksa Pharmaceuticals International, plc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Kiniksa Pharmaceuticals International, plc last report earnings?

Kiniksa Pharmaceuticals International, plc (KNSA) most recently filed an earnings 8-K with the SEC on Apr 28, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001730430-26-000017). This is Kiniksa Pharmaceuticals International, plc's most recent earnings filing of record — not a forecast of its next earnings date.

What is Kiniksa Pharmaceuticals International, plc's most recent earnings 8-K?

Kiniksa Pharmaceuticals International, plc's latest earnings 8-K (Item 2.02) was filed Apr 28, 2026 under accession 0001730430-26-000017. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Kiniksa Pharmaceuticals International, plc's latest earnings 8-K →
Look up any company's CIK number →